Investigational Drug Information for Seviteronel
✉ Email this page to a colleague
What is the development status for investigational drug Seviteronel?
Seviteronel is an investigational drug.
There have been 6 clinical trials for Seviteronel.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2015.
The most common disease conditions in clinical trials are Triple Negative Breast Neoplasms, Prostatic Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Innocrin Pharmaceutical, St Vincent's Hospital, Sydney, and National Cancer Institute (NCI).
There are seven US patents protecting this investigational drug and one hundred and thirty-six international patents.
Summary for Seviteronel
| US Patents | 7 |
| International Patents | 136 |
| US Patent Applications | 44 |
| WIPO Patent Applications | 72 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 2 (2015-05-01) |
| Vendors | 32 |
Recent Clinical Trials for Seviteronel
| Title | Sponsor | Phase |
|---|---|---|
| Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer | St Vincent's Hospital, Sydney | Phase 1/Phase 2 |
| Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma | St Vincent's Hospital, Sydney | Phase 2 |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) | Innocrin Pharmaceutical | Phase 1/Phase 2 |
Clinical Trial Summary for Seviteronel
Top disease conditions for Seviteronel
Top clinical trial sponsors for Seviteronel
US Patents for Seviteronel
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Seviteronel | ⤷ Try a Trial | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (La Jolla, CA) | ⤷ Try a Trial |
| Seviteronel | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| Seviteronel | ⤷ Try a Trial | Methods and compositions for identification of prostate cancer markers | Henry Ford Health System (Detroit, MI) | ⤷ Try a Trial |
| Seviteronel | ⤷ Try a Trial | Compositions and methods for treatment of prostate cancer | California Institute of Technology (Pasadena, CA) | ⤷ Try a Trial |
| Seviteronel | ⤷ Try a Trial | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Seviteronel
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Seviteronel | Australia | AU2015314772 | 2034-09-12 | ⤷ Try a Trial |
| Seviteronel | Canada | CA2960750 | 2034-09-12 | ⤷ Try a Trial |
| Seviteronel | European Patent Office | EP3191087 | 2034-09-12 | ⤷ Try a Trial |
| Seviteronel | World Intellectual Property Organization (WIPO) | WO2016040896 | 2034-09-12 | ⤷ Try a Trial |
| Seviteronel | Australia | AU2017261372 | 2036-05-05 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
